PAION AG : Un calendrier confirmé qui rassure
>Une trésorerie de 24,5 M€, guidance 2020 maintenue - Paion publie ce matin ses résultats des 9 mois et en profite pour faire un point sur son activité clinique et réglementaire. Tout d’abord, la biotech allemande dispose d’une trésorerie de 24,5 M€ nettement supérieure à fin du S1 (vs 12,4 M€ fin juin). Cette hausse s’explique essentiellement par des paiements de milestones suite à l’approbation de remimazolam aux USA. Le principal poste de dépenses reste les fr...Paion is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focusing on developing and commercializing drugs to be used in out-patient and hospital-based anesthesia, sedation and critical care services. Co.'s key compound is Remimazolam, an intravenous ultra short-acting and controllable anesthetic/sedative drug candidate in advanced stages of development for use in procedural sedation and general anesthesia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.